Your browser doesn't support javascript.
loading
Efficacy and safety of Hyper-CVAD regimen for treatment of aggressive T-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 28-32,36, 2018.
Article in Chinese | WPRIM | ID: wpr-691602
ABSTRACT
Objective To evaluate the safety and efficacy of Hyper-CVAD intensive chemotherapy regimen in patients with newly diagnosed aggressive T-cell lymphoma. Methods The efficacy, side effects and survival status were retrospectively analyzed in 34 patients with newly diagnosed aggressive T-cell lymphoma who received Hyper-CVAD regimen as induction therapy in Peking Union Medical College Hospital from September 2009 to December 2010. Results Of 34 patients, 28 cases (82.4 %) showed treatment response, including 10 cases (29.4 %) of complete response (CR). Eleven patients underwent stem cell transplantation, including 1 case of human leukocyte antigen-identical siblings allogeneic stem cell transplantation. The median follow-up was 16 months (1-82 months), and the overall survival (OS) rate of 1 or 3-year was 70.2 % and 41.1 % respectively, and progression-free survival (PFS) rate of 1 or 3-year was 49.3 % and 31.6 % respectively. The major adverse reaction was myelosuppresion, including 18 cases (52.9%) of myelosuppresion with grade Ⅳ. Three patients died of serious infection. Cox regression multifactor analysis showed CR was the only influencing factor for PFS (HR=6.118, 95%CI 1.327-28.206, P=0.020). Marrow involvement (HR= 0.270, 95 %CI 0.101-0.722, P= 0.009) and CR (HR= 6.669, 95 %CI 1.754-25.354, P= 0.005) were independent influencing factors for OS. Conclusions Hyper-CVAD regimen has a high response rate for aggressive T-cell lymphoma, but the lasting effectiveness and the short-term efficacy show unfavorable performances. Meanwhile, myelosuppression is serious and infection incidence is high. Autologous hematopoietic stem-cell transplantation after remission may improve the outcome.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Journal of Leukemia & Lymphoma Year: 2018 Type: Article